Adipositas und Herzinsuffizienz

Abstract

Obesity is on the on hand associated with classical risk factors for the development of chronic heart failure. On the other hand according to large scale epidemiologic trials a remarkable portion of the prevalence of chronic heart failure must be attributed to obesity alone. Explanations for the obesity associated heart failure have been given on pathophysiologic and molecular level. The central therapeutic approach to treat obesity related diseases is weight reduction. However, referring to large retrospective studies investigating the obesity paradox in chronic heart failure patients, existing overweight and obesity seem to be beneficial.

• Literatur

• 1 Deutsche Adipositas-Gesellschaft. Leitlinien der Deutschen Adipositas-Gesellschaft zur Therapie der Adipositas. Adipositas 1998; 16: 6-28
• 2 World Health Organization. WHO report obesity, preventing and managing the global epidemic. Geneva: World Health Organization; 1998
• 3 Lean MEJ, Han TS, Morrison CE. Waist as a measure for indicating need for weight management. Brit Med J 1995; 311: 158-160
• 4 Park YW, Zhu S, Palaniappan L et al. Prevalence and associated risk factor findings in the US population from the third national health and nutrition examination. Survey, 1988–1994. Arch Intern Med 2003; 163: 427-436
• 5 Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79
• 6 Beutner F, Teupser D, Gielen S et al. 2011 Rationale and design of the Leipzig LIFE Heart Study: phenotyping and cardiovascular characteristics of patients with coronary artery disease. J PLoS One 2011; 612: e29070
• 7 Troiano RP, Frongillo EA Jr, Sobal J et al. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord 1996; 20: 63-75
• 8 Peeters A, Barendregt JJ, Willekens F et al. Obesity in adulthood and its consequences for life expectancy: a life table analysis. Ann Intern Med 2003; 138: 24-32
• 9 Fischer M, Baessler A, Holmer S et al. Epidemiology of left ventricular systolic dysfunction in the general population of Germany: results of an echocardiographic study of a large population-based sample. Z Kardiol 2003; 92: 294-302
• 10 Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313
• 11 Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure: developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235
• 12 Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 1992; 70: 921-924
• 13 Carpenter HM. Myokardial Fat Infiltration. Am Heart J 1962; 63: 491-496
• 14 De Scheerder I, Cuvelier C, Verhaaren R et al. Restrictive cardiomyopathy caused by adipositas cordis. Eur Heart J 1987; 86: 661-663
• 15 Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791-2801
• 16 Yan J, Young ME, Cui L et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009; 119: 2818-2828
• 17 van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 2011; 92: 10-18
• 18 Pulakat L, Aroor AR, Gul R et al. Cardiac insulin resistance and microRNA modulators. Exp Diabetes Res 2012; 2012: 654904
• 19 Alpert MA, Lambert CR, Panayiotou H et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995; 76: 1194-1197
• 20 Lauer MS, Anderson KM, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1992; 19: 130-134
• 21 Nakajima T, Fujioka S, Tokunaga K et al. Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. Circulation 1985; 71: 481-486
• 22 Yoshinaga M, Yuasa Y, Hatano H et al. Effect of total adipose weight and systemic hypertension on left ventricular mass in children. Am J Cardiol 1995; 76: 785-787
• 23 Lesser GT, Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 1967; 22: 621-630
• 24 Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225-236
• 25 Medeiros C, Frederico MJ, da Luz G et al. Exercise training reduces insulin resistance and upregulates the mTOR/p70S6k pathway in cardiac muscle of diet-induced obesity rats. J Cell Physiol 2011; 226: 666-674
• 26 Licata G, Volpe M, Scaglione R et al. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994; 23 : I20-I24
• 27 Maoz E, Shamiss A, Peleg E et al. The role of atrial natriuretic peptide in natriuresis of fasting. J Hypertens 1992; 10: 1041-1044
• 28 Van Heek M, Compton DS, France CF et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385-390
• 29 Carlyle M, Jones OB, Kuo JJ et al. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002; 39: 496-501
• 30 Rajapurohitam V, Gan XT, Kirshenbaum LA et al. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003; 93: 277-279
• 31 Jia Y, Takimoto K. Mitogen-activated protein kinases control cardiac KChIP2 gene expression. Circ Res 2006; 98: 386-393
• 32 Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001; 79: 21-29
• 33 Tuck ML, Sowers J, Dornfeld L et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933
• 34 Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
• 35 Keenan KP, Hoe CM, Mixson L et al. Diabesity: a polygenic model of dietary-induced obesity from ad libitum overfeeding of Sprague-Dawley rats and its modulation by moderate and marked dietary restriction. Toxicol Pathol 2005; 33: 650-674
• 36 DasGupta P, Ramhanmdany E, Brigden G et al. Improvement in left ventricular function after rapid weight loss in obesity. Eur Heart J 1992; 13: 1060-1066
• 37 Marfella R, Esposito K, Siniscalchi M et al. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 2004; 27: 47-52
• 38 Wong CY, Byrne NM, O'Moore-Sullivan T et al. Effect of weight loss due to lifestyle intervention on subclinical cardiovascular dysfunction in obesity body mass index >30 kg/m2. Am J Cardiol 2006; 98: 1593-1598
• 39 Hinderliter A, Sherwood A, Gullette EC et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med 2002; 162: 1333-1339
• 40 Ploug T, van Deurs B, Ai H et al. Analysis of GLUT4 distribution in whole skeletal muscle fibers: identification of distinct storage compartments that are recruited by insulin and muscle contractions. J Cell Biol 1998; 142: 1429-1446
• 41 Sjostrom L, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752
• 42 Sjöström L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65
• 43 Alpert MA, Lambert CR, Terry BE et al. Effect of weight loss on left ventricular diastolic filling in morbid obesity. Am J Cardiol 1995; 76: 1198-1201
• 44 Syed M, Rosati C, Torosoff MT et al. The impact of weight loss on cardiac structure and function in obese patients. Obes Surg 2009; 19: 36-40
• 45 Fleischmann E, Teal N, Dudley J et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55: 1560-1567 (Erratum in: Kidney Int 2000; 572: 760)
• 46 Gruberg L, Weissman NJ, Waksman R et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?. J Am Coll Cardiol 2002; 39: 578-584
• 47 Curtis JP, Selter JG, Wang Y et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005; 165: 55-61 (Erratum in: Arch Intern Med 2008; 1686: 567)
• 48 McAuley P, Myers J, Abella J et al. Body mass, fitness and survival in veteran patients: another obesity paradox?. Am J Med 2007; 120: 518-524
• 49 Uretsky S, Messerli FH, Bangalore S et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863-870
• 50 Galal W, van Gestel YR, Hoeks SE et al. The obesity paradox in patients with peripheral arterial disease. Chest 2008; 134: 925-930
• 51 Badheka AO, Rathod A, Kizilbash MA et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010; 123: 646-651
• 52 McAuley PA, Blair SN. Obesity paradoxes. J Sports Sci 2011; 29: 773-782
• 53 Oreopoulos A, Padwal R, Kalantar-Zadeh K et al. Related citations 6. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008; 156: 13-22
• 54 Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-1053
• 55 Haass M, Kitzman DW, Anand IS et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-331
• 56 Kenchaiah S, Pocock SJ, Wang D et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 116: 627-636